Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Muth

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Pageof 2